Treatment of Rheumatoid Arthritis
Introduction to Conventional Disease-Modifying Antirheumatic Drugs (DMARDs)
- The American College of Rheumatology recommends methotrexate as the first-line treatment for rheumatoid arthritis, unless contraindicated, in which case sulfasalazine or leflunomide may be considered, with penicillamine only when multiple conventional and biologic DMARDs have failed 1, 2, 3, 4
- Methotrexate dosing should be at therapeutic levels (15 mg/week orally with folic acid 1 mg/day, optimizing to 20-25 mg/week within the first 3 months) 5, 2
Indications and Usage
- Sulfasalazine is indicated for early or established rheumatoid arthritis, especially when methotrexate is contraindicated, as part of triple therapy (with methotrexate and hydroxychloroquine), or in patients with mild to moderate disease activity 3, 4
- Leflunomide has similar clinical efficacy to methotrexate in established and recent rheumatoid arthritis, according to the European League Against Rheumatism 1
- Sulfasalazine is considered the third alternative, slightly less effective than leflunomide and methotrexate in the long term, as stated by the European League Against Rheumatism 1
Dosage and Administration
- The initial dose of sulfasalazine is 500 mg/day, gradually increasing to a maintenance dose of 2-3 g/day divided into 2-3 doses, with a therapeutic dose of 3-4 g/day in divided doses at intervals not exceeding 8 hours 3, 4
- Penicillamine is started at a low dose (125-250 mg/day) and gradually increased to 500-750 mg/day divided into 2-3 doses, administered on an empty stomach, at least 1 hour before or 2 hours after meals 3, 4
- Leflunomide dosing should be 10-20 mg/day, with a loading dose of 100 mg/day for 3 days 2
Contraindications and Precautions
- Sulfasalazine is contraindicated in patients with intestinal or urinary obstruction, porphyria, or hypersensitivity to sulfasalazine, its metabolites, sulfonamides, or salicylates 3, 4
- Penicillamine is contraindicated in patients with severe renal insufficiency, history of agranulocytosis, aplastic anemia, or thrombocytopenia related to penicillamine, pregnancy (category D), or lactation 3, 4
- Leflunomide is contraindicated in pregnancy due to teratogenic potential, and women of childbearing potential should use effective contraception during treatment, as advised by the American College of Rheumatology 2
Adverse Effects
- Common adverse effects of sulfasalazine include gastrointestinal symptoms (nausea, vomiting, abdominal pain, diarrhea), cutaneous reactions (rash), hematologic effects (myelosuppression), and neurologic effects (headache, dizziness) 3, 4
- Penicillamine can cause cutaneous reactions (rash), hematologic effects (thrombocytopenia, leukopenia, agranulocytosis), renal effects (proteinuria, nephrotic syndrome), autoimmune reactions (myasthenia gravis, Goodpasture's syndrome, drug-induced lupus), and gastrointestinal symptoms (nausea, vomiting, anorexia) 3, 4
- Common adverse events of leflunomide include gastrointestinal symptoms, allergic reactions, reversible alopecia, and elevated liver enzymes, which can be managed by dose reduction, symptomatic therapy, and close monitoring, as recommended by the American College of Rheumatology 2
Monitoring and Pregnancy
- The American College of Rheumatology recommends regular monitoring of hematologic parameters and liver function for both sulfasalazine and penicillamine 3, 4
- Sulfasalazine is considered safe during pregnancy, unlike many other DMARDs, according to the European League Against Rheumatism 4
- Disease activity should be monitored every 1-3 months, and response to treatment should be evaluated at 3 months, which is a critical point for predicting long-term outcomes, as recommended by the American College of Rheumatology and the European League Against Rheumatism 4, 2, 5
Treatment Algorithm
- For patients without poor prognostic factors, the European League Against Rheumatism recommends adding or switching to another conventional synthetic DMARD (leflunomide or sulfasalazine) if there is an inadequate response to methotrexate monotherapy after 3-6 months 2
- For patients with poor prognostic factors, the European League Against Rheumatism suggests adding a biologic DMARD (preferably TNF inhibitor) or JAK inhibitor, with poor prognostic factors including high RF/ACPA levels, high disease activity, early joint damage, and failure of 2 csDMARDs 2
- A biologic DMARD (preferably a TNF inhibitor) or a JAK inhibitor should be added to MTX for patients with unfavorable prognostic factors, which can provide greater efficacy, as recommended by the American College of Rheumatology and the European League Against Rheumatism 2, 5
Non-Pharmacologic Interventions
- Incorporate exercise as part of comprehensive management, including dynamic exercise programs that incorporate both aerobic exercise and progressive resistance training 5, 6, 7
- Consider occupational therapy for instruction about joint protection and assistive devices 5
- Overlooking the importance of non-pharmacologic interventions like exercise and rehabilitation can lead to inadequate management of rheumatoid arthritis, according to the American College of Rheumatology 6, 7
Special Considerations
- Short-term glucocorticoids, such as low-dose prednisone (≤10 mg/day), can be added as bridge therapy during the first 6 months and tapered as rapidly as clinically feasible, as recommended by the American College of Rheumatology and the European League Against Rheumatism 8, 4, 1, 2
- Inadequate dosing, premature discontinuation, omitting folic acid, delayed treatment, and inadequate monitoring are common pitfalls in MTX treatment, highlighting the importance of optimal dosing, sufficient treatment duration, and regular monitoring, as suggested by 5
- Delaying the start of treatment is one of the most important causes of delay in establishing effective treatment, and early and aggressive treatment with DMARDs, particularly MTX, is essential for controlling inflammation, preventing joint damage, and improving quality of life in patients with rheumatoid arthritis, as recommended by the American College of Rheumatology and the European League Against Rheumatism 8, 4, 9, 1